Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A study was undertaken whereby a set of standardized (simulated) patients visited general practitioners without being detected, in a health care system where doctors had fixed patient lists. Thirty nine general practitioners were each visited during normal surgery hours by four standardized patients who were designed to be indistinguishable from real patients. The objective of the study was to see whether the actual performance of general practitioners, as assessed by standardized patients, met predetermined consensus standards of care for actual practice. The patients presented standardized accounts of headache,
diarrhoea
, shoulder pain and
diabetes
. The mean group scores of the doctors on the predefined standards of care for the different complaints ranged from 33 to 68%. The results show that standardized patients may be the method of choice in the assessment of the quality of actual care of doctors. It is hypothesized that the substandard scores of the doctors do not reflect inadequate competence, but are a result of the difference between competence and performance.
...
PMID:Assessment of the performance of general practitioners by the use of standardized (simulated) patients. 193 Dec 15
Reovirus type 2 that had been isolated from a cow with
diarrhoea
and passaged in bovine kidney cell culture produced a Type 1 (insulin-dependent)
diabetes
-like syndrome when inoculated into NC mice. The infection resulted in insulitis and destruction of islet cells. Viral antigens were found in islet cells by staining with fluorescein-labelled antibody to reovirus type 2. The destruction of islet cells resulted in abnormalities shown on glucose tolerance testing. Studies on the susceptibility of the host showed that only certain strains of mice had overtly abnormal glucose tolerance tests when infected with reovirus type 2. To assess the immunological role in the pathogenesis of reovirus type 2-induced
diabetes
, infected mice were subjected to immunosuppressive or thymic hormone treatment. The administration of either anti-thymocyte serum or serum thymic factor reduced or prevented the development of the
diabetes
-like syndrome, while Arg-Lys-Asp-Val-Try did not show any therapeutic effects.
...
PMID:Reovirus type 2-induced diabetes in mice prevented by immunosuppression and thymic hormone. 216 69
After an acute episode of pancreatitis, a 63-year-old man was found to have a pancreatic glucagonoma. The tumor was resected without evidence of metastases. Three years later he had symptoms of uncontrolled
diabetes
, no skin lesions, and
diarrhea
and was found to have a pancreatic pseudocyst and multiple hepatic metastases. Glucagon concentrations were raised but were suppressible by glucose and somatostatin and responded to arginine stimulation. He was treated for 6 months with octreotide (Sandostatin), which reduced his symptoms; the pseudocyst resolved, but liver metastases continued to grow. Although spontaneous resolution of the pseudocyst is possible, this case appears to illustrate differences in sensitivity of endocrine and exocrine tissues to suppression by Sandostatin.
...
PMID:Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses. 216 87
Fluid therapy is practical and beneficial when properly administered to cattle. Mature cattle are more frequently alkalotic than acidotic, so nonalkalizing solutions are usually indicated. Exceptions include cattle with choke, carbohydrate engorgement,
diabetes mellitus
, and, occasionally, renal disease,
diarrhea
, and fatty liver/ketosis. Most dehydrated cattle need supplemental potassium and calcium as well as sodium, chloride, and water. Intravenous administration is indicated in patients with obstructive gastrointestinal disease and those with severe dehydration. Oral or intraruminal administration is less expensive and often very effective.
...
PMID:Fluid therapy in mature cattle. 217 37
A series of 10 cases of chronic calcifying pancreatitis from central Tunisia are reported. The mean age at presentation was 23 years and the male to female ratio was 1.5. The main clinical manifestations of the disease were abdominal pain (eight cases), weight loss (four cases), and
diarrhea
(three cases).
Diabetes
was recorded in four cases. The etiological investigations yielded negative results in all the patients. It is concluded that central Tunisia should be added to the regions where juvenile chronic calcifying pancreatitis of the "tropical type" may be observed.
...
PMID:Juvenile idiopathic chronic calcifying pancreatitis: report of 10 cases from central Tunisia. 218 58
It has been proposed that lowering glomerular pressure in children with insulin-dependent
diabetes mellitus
will reduce microalbuminuria and that this reduction may preserve renal function. We therefore conducted a double-blind, placebo-controlled, crossover trial to compare 3 months of treatment with the angiotensin converting enzyme inhibitor captopril (0.9 mg/kg/day), and 3 months of placebo administration to 12 normotensive adolescents with insulin-dependent
diabetes mellitus
, 11 with microalbuminuria (albumin excretion rate of 15 to 200 micrograms/min) and one with early overt nephropathy. Mean age (+/- SD) was 14.4 +/- 1.7 years, and disease duration was 5.1 +/- 2.5 years. Albumin excretion rate decreased significantly during captopril therapy (baseline 78 +/- 114 micrograms/min; mean of monthly measurements 38 +/- 55 micrograms/min vs placebo 78 +/- 140 micrograms/min; p less than 0.001). During captopril therapy, albumin excretion was reduced by 41 +/- 44% and decreased in 10 of 12 subjects, but was unchanged in two, one with a borderline albumin excretion rate (16.3 micrograms/min) and one with
diabetes
of short duration (2.9 years). Plasma renin activity rose significantly during captopril therapy, and mean arterial pressure decreased slightly (placebo 81 +/- 7 mm Hg; captopril 76 +/- 5 mm Hg; p = 0.004). After 3 months of captopril treatment, glomerular filtration rate and renal plasma flow did not change significantly. Hemoglobin Alc values remained stable during the study. The only side effect of captopril was
diarrhea
in one patient. We conclude that, in the short term, captopril is effective in decreasing albumin excretion rate in normotensive children with insulin-dependent
diabetes mellitus
and microalbuminuria, without significant side effects. Longer trials are indicated in an attempt to delay or prevent overt nephropathy.
...
PMID:Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. 219 59
Growth hormone is assumed to be involved in the development of diabetic retinopathy. In a randomized study we evaluated the possible effects of one year treatment with a somatostatin (SRIH) analogue, octreotide, on early retinopathy and on metabolism in Type I (insulin-dependent)
diabetes mellitus
. Eleven patients were allocated to treatment with a continuous sc infusion of 400 micrograms octreotide per day and 9 served as controls. Only 7 patients from each group completed the study. Three octreotide-treated patients left the study owing to severe
diarrhea
. The subjects were evaluated at entry, after 2, 6 and 12 months treatment, and 2 months after withdrawal. Octreotide induced a decrease in GH secretion, expressed as the area under the 24 h serum GH profiles (p less than 0.05), and of the serum levels of IGF-I (p less than 0.05). The entire decline in GH levels occurred during the daytime, whereas the nocturnal levels were unaffected. Retinopathy, as assessed by determination of the blood retina barrier permeability, by colour fundus photography, and flurescein angiography was unchanged in both groups. Apart from a decline in insulin requirements, octreotide had no major effect on glycemic control, but induced a mild transient pituitary hypothyroidism, not clinically relevant. We conclude that treatment with octreotide for one year has modest effects on GH, IGF-I, and glucose metabolism, but has no significant effect on early retinopathy in Type I (insulin-dependent)
diabetes
.
...
PMID:Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. 219 45
This review of the literature is designed to identify the state of our knowledge about the ileal, colonic and biliary damage arising in
diabetes mellitus
. The approach is primarily clinical with the emphasis on the major symptoms involved:
diarrhea
, constipation and anal sphincter incontinence. The most common symptom, found in 20% of diabetics with neurological disease, is constipation. While the peculiar features of diabetic
diarrhea
have been well described, there is considerable controversy over its pathogenesis. As for sphincter dysfunction, manometric examinations will already reveal the autonomic neuropathy involved in the early asymptomatic phase. There is considerable debate over the possible involvement of the gallbladder in
diabetes mellitus
. Some believe that the autonomic neuropathy is involved in the pathogenesis of the lithiasis and helps to mask the pain in cholecystitis as well.
...
PMID:[Diabetic enteropathy]. 219 94
The Ticlopidine Microangiopathy of
Diabetes
study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years. The mean yearly increase in definite microaneurysms on fluorescein angiograms was significantly higher (P = .03) in the placebo group (1.44 +/- 4.67) than in the ticlopidine group (0.48 +/- 5.79). Significance was limited to primary analysis using a quality angiographic coefficient for definite microaneurysms in patients with at least three readable angiograms over a 3-year period. Ticlopidine was significantly beneficial to insulin-treated diabetic patients, inducing a sevenfold reduction of the yearly microaneurysm progression (0.23 +/- 6.66) compared with the placebo (1.57 +/- 5.29) (P = .03). Among insulin-treated diabetic patients, fewer had development of new vessels in the ticlopidine group than in the placebo group, at borderline statistical significance (P = .056). Overall retinopathy progression was significantly less severe in the ticlopidine group (P = .04). Adverse reactions associated with ticlopidine included neutropenia (severe in one patient) with no clinical complications,
diarrhea
, or rash. This study demonstrated that ticlopidine slows down the progression of nonproliferative diabetic retinopathy.
...
PMID:Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. 224 43
The administration of metformin, as glucophage retard, at bedtime instead of supper time may improve
diabetes
control by reducing morning hyperglycemia. This modification of glucophage treatment was tried in 3 groups of diabetic patients: I. those with secondary failure of routine treatment with sulfonylurea (SU) and glucophage; II. those with combined SU and bedtime insulin; III. Type 1 patients with early morning hypoglycemia. The first 3 months of observation in 258 patients showed that 136 (52.7%) reacted very well to the change. In Group I the addition of insulin to SU could be postponed. In Group II, night insulin could be reduced or eliminated. In Group III, evening or night insulin could be reduced by up to 70%. There was no early morning hypoglycemia nor morning hyperglycemia. The success rate in the 2 Type 2 groups was better (72% and 60%) than in the Type 1 group (34%). 30 patients (11.6%) had to stop the treatment because of side effects of the glucophage (mainly
diarrhea
or nausea). So far, we have found no clinical signs that might indicate which patients might benefit from this modification of treatment. A fasting blood sugar done within 2-3 days after the change in treatment may immediately indicate whether the new treatment is effective.
...
PMID:[Bedtime administration of metformin may reduce insulin requirements]. 225 95
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>